Nighttime dosing assures postdistribution sampling for therapeutic drug monitoring of digoxin

Clinical Chemistry

Volumn 42, Issue 1, 1996, Pages 45-49

  Bernard, David W ^a   Bowman, Richard L ^a   Grimm, Freddy A ^a   Wolf, Bryan A ^a   Simson, Michael B ^a   Shaw, Leslie M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

blood sampling; pharmacokinetics

Indexed keywords

DIGOXIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NIGHT; PHLEBOTOMY; RETROSPECTIVE STUDY; TIME;

EID: 0030034438     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.1.45     Document Type: Article

References (13)

1. Rifkin S. Top 200 survey. Am Drug 1994;Feb:27-34.
2. Smith TW. Digitalis toxicity: epidemiology and clinical use of serum concentration measurements. Am J Med 1975;58:470-6.
3. Huffman DH, Crow JW, Pentikainen P, Azarnoff DL. Association between clinical cardiac status, laboratory parameters, and digoxin usage. Am Heart J 1976;91:28-34.
4. Reuning RH, Garaets DR, Rocci ML Jr, Vlasses PH. Digoxin. In: Evans WE, Schentag JJ, Jusko WJ, Relling MV. Applied pharmacokinetics: principles of therapeutic drug monitoring, 3rd ed. Vancouver, WA: Applied Therapeutics, 1992: Ch. 20, 1-48.
5. Reuning RH, Sams RA, Notari R. Role of pharmacokinetics in drug dosage adjustments. 1. Pharmacologic effect kinetics and apparent volume of distribution of digoxin. J Clin Pharmacol 1973;13: 127-41.
6. Hallworth, Capps. Theoretical considerations. Therapeutic drug monitoring and clinical biochemistry. London: ACB Venture Publications, 1993;1-28.
7. Clague HW, Twum-Barima Y, Carruthers SG. An audit of requests for therapeutic drug monitoring of digoxin: problems and pitfalls. Ther Drug Monit 1983;5:249-54.
8. Gibb I, Cowan JC, Parnham AJ, Thomas TH. Use and misuse of a digoxin assay service. Br Med J 1986;293:678-80.
9. Kumana CR, Chan YM, Kou M. Audit exposes flawed blood sampling for "digoxin levels." Ther Drug Monit 1992;14:155-8.
10. Copeland RJ, Thorpe H, Kay EA. Inappropriate digoxin monitoring. J Clin Pharm Ther 1992;17:173-4.
11. Matzuk MM, Shlomchik M, Shaw LM. Making digoxin therapeutic drug monitoring more effective. Ther Drug Monit 1991;13:215-9.
12. Howanitz PJ, Steindel SJ. Digoxin therapeutic drug monitoring practices: a College of American Pathologists Q-probes study of 666 institutions and 18 679 toxic levels. Arch Pathol Lab Med 1993;117:684-90.
13. Piergies AA, Worwag EM, Atkinson AJ. A concurrent audit of high digoxin plasma levels. Clin Pharmacol Ther 1994;55:353-8.